Manufacturing of biopharmaceuticals is subjected to many changes, such as rising volume demands by meeting more stringent safety requirements. These prevailing conditions challenging conventional manufacturing platforms to re-think and re-innovate, which have not adapted sufficiently to address these changes at low cost. Oncosmis' (AcceTT® and BacSec®) technology is designed to meet these demands while keeping the yield of biologic drug at a much higher level compared to current competitors. AcceTT® and BacSec® have established platform technologies at lab scale and would ideally be suited for the development and large-scale manufacturing of a wide range of biologic drugs in both CHO cells and E. coli.
AcceTT®: This technology facilitates rapid and high yield production of biologics couple with robust cell growth. AcceTT® is a fully integrated technology platform that comprise of vectors, media toolbox and cell line to establish ultra high producing cells in short period of time.
AcceTT® for mAb stoichiometry and higher yield: To address synchronized higher subunit expression and secretion of mAbs, a new regulator element has been introduced to match stoichiometry of both light and heavy chains of mAb. (P+ = addition new regulatory element).
BacSec® technology for toxin-free production of biologics: BacSec® technology is a fully integrated platform comprises of plasmid, bacteria and media formulation for secretion of proteins into media without disintegration of Bacteria.
BacSec® technology: BacSec® technology not only provides a tool to circumvent toxicity and other contamination issues but also simply the downstream process for production of therapeutic proteins in E. coli.